Streamex Corp. (STEX) · Oct 9, 2026 · Delisting
Nasdaq deficiency — 180-day cure period ends April 5, 2027
Streamex received a Nasdaq delisting warning after 30 sessions below $1, starting a 180-day cure period and raising reverse-split risk.
Streamex is still an early-stage company building tokenized gold and commodity infrastructure while retaining a biomedical technology business from its legacy operations. The filing adds a real listing risk to that transition: Nasdaq says the stock failed to maintain the required $1 closing bid price for 30 consecutive business days. 〔0〕
This is a warning, not an immediate delisting: Streamex has until April 5, 2027 to produce a $1 closing bid for at least 10 consecutive business days, with a possible additional 180-day period if it meets other listing standards. 〔1〕 That gives management time, but the path may require a reverse stock split, which the filing explicitly identifies as an available option.
The downside trigger is more severe if the share price deteriorates further: a closing bid of $0.10 or less for 10 straight trading days would lead to a Staff Delisting Determination. The notice does not interrupt current trading, but it adds a concrete deadline and a potential capital-structure action to a company already trying to establish its new tokenization strategy. 〔2〕
Bottom line: This does not change Streamex’s operating plan today, but it makes execution and share-price support an immediate corporate priority. The event is negative because the company must now solve a Nasdaq compliance problem or risk losing its listing.
Regain $1 bid price by April 5, 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!